2 results match your criteria: "Department of Medicine Showa General Hospital Tokyo Japan.[Affiliation]"
Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.
Respirol Case Rep
February 2021
Division of Respiratory Medicine, Department of Medicine Showa General Hospital Tokyo Japan.
See related Letter.
View Article and Find Full Text PDFIdiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.
Respirol Case Rep
November 2020
Division of Respiratory, Department of Medicine Showa General Hospital Tokyo Japan.
Article Synopsis
- * Initially treated with prednisolone and then mepolizumab, he experienced disease progression at a low prednisolone dose and switched to benralizumab.
- * The treatment with benralizumab led to remission, showcasing its potential effectiveness in targeting IL-5R and reducing eosinophil levels in I-HES patients.